CCC
GILD icon

Crescent Capital Consulting’s Gilead Sciences GILD Stock Holding History

Crescent Capital Consulting’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$39K Buy
532
+200
+60% +$13.8K 0.01% 308
2021
Q3 		$23K Hold
332
– – ﹤0.01% 376
2021
Q2 		$23K Buy
332
+32
+11% +$2.14K ﹤0.01% 331
2021
Q1 		$19K Sell
300
-100
-25% -$6.45K ﹤0.01% 352
2020
Q4 		$23K Buy
+400
New +$24.1K 0.01% 313

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Crescent Capital Consulting's GILD Position: Q4 2021 in Review

Crescent Capital Consulting increased its Gilead Sciences (GILD) stake by 60% in Q4 2021, buying an estimated $13.8K and bringing the position to 532 shares worth $39K. The position accounts for 0.01% of the portfolio, ranked #308.

Crescent Capital Consulting first reported a position in GILD in Q4 2020 and has held it in 5 quarters since. 1,682 funds tracked by Wall St. Rank hold GILD as of Q4 2021.

  • Crescent Capital Consulting held 532 shares of Gilead Sciences worth $39K as of Q4 2021.
  • Crescent Capital Consulting bought 200 Gilead Sciences shares in Q4 2021, an estimated $13.8K.
  • Gilead Sciences made up 0.01% of Crescent Capital Consulting's portfolio in Q4 2021, its #308 holding.
  • Crescent Capital Consulting first reported a position in Gilead Sciences in Q4 2020 and has held it in 5 quarters since.
  • 1,682 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.